$210 Million is the total value of Prosight Management, LP's 47 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 81.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $13,251,000 | +31.2% | 115,800 | +28.7% | 6.30% | +45.4% |
| BMY | Buy | BRISTOL-MYERS SQUIBB CO | $11,184,000 | +61.2% | 185,500 | +57.2% | 5.32% | +78.6% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $11,160,000 | -12.9% | 114,554 | +39.5% | 5.31% | -3.5% |
| CUE | Buy | CUE BIOPHARMA INC | $10,685,000 | +40.5% | 709,936 | +128.8% | 5.08% | +55.7% |
| BAX | Buy | BAXTER INTL INC | $9,811,000 | +168.1% | 122,000 | +187.1% | 4.67% | +197.0% |
| AUPH | Buy | AURINIA PHARMACEUTICALS INC | $8,764,000 | +486.2% | 595,000 | +546.7% | 4.17% | +549.2% |
| CI | Buy | CIGNA CORP NEW | $7,962,000 | +10.2% | 47,000 | +22.1% | 3.79% | +22.1% |
| EHC | Buy | ENCOMPASS HEALTH CORP | $7,013,000 | +244.3% | 107,921 | +228.0% | 3.34% | +281.7% |
| Buy | APTOSE BIOSCIENCES INC | $6,835,000 | +38.3% | 1,139,094 | +45.5% | 3.25% | +53.3% | |
| QURE | Buy | UNIQURE NV | $6,313,000 | -2.1% | 171,429 | +19.8% | 3.00% | +8.5% |
| PRTA | New | PROTHENA CORP PLC | $5,447,000 | – | 545,195 | +100.0% | 2.59% | – |
| MTCR | New | METACRINE INC | $5,297,000 | – | 518,796 | +100.0% | 2.52% | – |
| New | ALEXION PHARMACEUTICALS INCcall | $3,891,000 | – | 34,000 | +100.0% | 1.85% | – | |
| TBIO | Buy | TRANSLATE BIO INC | $3,839,000 | +139.3% | 282,100 | +215.2% | 1.83% | +165.0% |
| ZGNX | Buy | ZOGENIX INC | $3,243,000 | -18.0% | 180,924 | +23.6% | 1.54% | -9.1% |
| ORGO | Buy | ORGANOGENESIS HLDGS INC | $2,598,000 | +26.3% | 676,553 | +26.3% | 1.24% | +40.0% |
| CARA | Buy | CARA THERAPEUTICS INC | $2,222,000 | +49.4% | 174,644 | +100.8% | 1.06% | +65.7% |
| AMRX | New | AMNEAL PHARMACEUTICALS INC | $1,989,000 | – | 512,659 | +100.0% | 0.95% | – |
| ONEM | New | 1LIFE HEALTHCARE INC | $1,865,000 | – | 65,778 | +100.0% | 0.89% | – |
| KZR | New | KEZAR LIFE SCIENCES INC | $1,771,000 | – | 365,981 | +100.0% | 0.84% | – |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $1,661,000 | +31.2% | 244,252 | +44.9% | 0.79% | +45.5% |
| QDEL | New | QUIDEL CORP | $1,645,000 | – | 7,500 | +100.0% | 0.78% | – |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $1,297,000 | -10.9% | 301,678 | +21.6% | 0.62% | -1.3% |
| BTAI | New | BIOXCEL THERAPEUTICS INC | $1,292,000 | – | 29,800 | +100.0% | 0.62% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $1,224,000 | – | 15,826 | +100.0% | 0.58% | – |
| IMTX | New | IMMATICS N.V | $1,204,000 | – | 113,460 | +100.0% | 0.57% | – |
| NLTX | New | NEOLEUKIN THERAPEUTICS INC | $797,000 | – | 66,376 | +100.0% | 0.38% | – |
| KIDS | New | ORTHOPEDIATRICS CORP | $386,000 | – | 8,399 | +100.0% | 0.18% | – |
| New | REATA PHARMACEUTICALS INCcall | $156,000 | – | 1,600 | +100.0% | 0.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.